



US005674836A

**United States Patent** [19][11] **Patent Number:** **5,674,836****Kilbourn et al.**[45] **Date of Patent:** **\*Oct. 7, 1997****[54] TREATMENT OF SEPTIC SHOCK WITH IRON-CONTAINING HEMOPROTEIN**

[75] Inventors: **Robert G. Kilbourn**, Houston, Tex.;  
**Joseph De Angelo**, Hamtramck, Mich.;  
**Joseph Bonaventura**, Beaufort, N.C.

[73] Assignees: **Board of Regents, The University of Texas System**, Austin, Tex.; **Duke University**, Durham; **Apex Bioscience, Inc.**, Research Triangle Park, both of N.C.

[\*] Notice: The portion of the term of this patent subsequent to Mar. 22, 2011, has been disclaimed.

[21] Appl. No.: **184,255**

[22] Filed: **Jan. 18, 1994**

**Related U.S. Application Data**

[63] Continuation of Ser. No. 838,603, Feb. 19, 1992, Pat. No. 5,296,466.

[51] Int. Cl.<sup>6</sup> ..... **A61K 38/42**

[52] U.S. Cl. .... **514/6; 514/12; 514/21; 424/85.2; 530/385**

[58] Field of Search ..... **514/6, 12, 21; 530/385; 424/85.2**

**[56] References Cited****U.S. PATENT DOCUMENTS**

4,061,736	12/1977	Morris et al.	424/177
4,584,130	4/1986	Bucci et al.	260/112
4,598,064	7/1986	Walder	514/6
4,751,068	6/1988	Bickar et al.	423/437
5,028,627	7/1991	Kilbourn et al.	514/565
5,082,642	1/1992	Bickar et al.	423/402
5,334,706	8/1994	Przybelski	530/385
5,510,464	4/1996	Przybelski	530/385

**FOREIGN PATENT DOCUMENTS**

WO91/04023	4/1991	WIPO
WO91/04024	4/1991	WIPO
WO91/84023	4/1991	WIPO
WO93/00893	1/1993	WIPO

**OTHER PUBLICATIONS**

Kilbourn et al., "N<sup>G</sup>-Methyl-L-arginine Inhibits Tumor Necrosis Factor-Induced Hypotension: Implications for the Involvement of Nitric Oxide." *Proc. Natl. Acad. Sci. USA*, 87:3629-3632, 1990, published in U.S.A.

Palmer et al., "Nitric Oxide Release Accounts for the Biological Activity of Endothelium-Derived Relaxing Factor." *Nature*, 327:524-526, 1987, published in England.

Moncada et al., "Generation of Prostacycline and Endothelium-Derived Relaxing Factor from Endothelial Cells." IN: Golles, G., Legran J.Y., and Nurden A. eds., *Biology and Pathology of Platelets—Vessel Wall Interactions*, pp. 289-304, 1986, published in London.

Kilbourn et al., "Activated Macrophages Secrete a Soluble Factor that Inhibits Mitochondrial Respiration of Tumor Cells." *The Journal of Immunology*, 133(5):2577-2581, 1984, published in Baltimore, MD.

Kilbourn & Belloni, "Endothelial Cell Production of Nitrogen Oxides in Response to Interferon  $\gamma$  in Combination with Tumor Necrosis Factor, Interleukin-1, or Endotoxin." *Journal of the National Cancer Institute*, 82:772-776, 1990, published in U.S.A.

Aisaka et al., "N<sup>G</sup>-Methylarginine, an Inhibitor of Endothelium-Derived Nitric Oxide Synthesis, is a Potent Pressor Agent in the Guinea Pig: Does Nitric Oxide Regulate Blood Pressure in Vivo?" *Biochemical and Biophysical Research Communications*, 160(2):881-886, 1989, published in San Diego, CA.

Vallance et al., "Effects of Endothelium-Derived Nitric Oxide on Peripheral Arteriolar Tone in Man." *Lancet*, 28:997-999, 1989, published in Great Britain.

Kilbourn et al., "Reversal of Endotoxin-Mediated Shock by N<sup>G</sup>-Methyl-L-Arginine, an Inhibitor of Nitric Oxide Synthesis." *Biochemical and Biophysical Research Communications*, 172(3):1132-1138, 1990, published in San Diego, CA.

Gross et al., "Cytokine-activated Endothelial Cells Express an Isotype of Nitric Oxide Synthase Which is Tetrahydrobiopterin-Dependent, Calmodulin-Independent and Inhibited by Arginine Analogs with a Rank-Order of Potency Characteristic of Activated Macrophages." *Biochemical and Biophysical Research Communications*, 178(3):823-829, 1991, published in San Diego, CA.

Schmidt et al., "Insulin Secretion from Pancreatic B Cells Caused by L-Arginine-Derived Nitrogen Oxides." *Science*, 255:721-723, 1992, published in Washington, DC.

Sakuma et al., "Identification of Arginine as a Precursor of Endothelium-Derived Relaxing Factor." *Proc. Natl. Acad. Sci. USA*, 85:8664-8667, 1988, published in U.S.A.

Stuehr & Marietta, "Induction of Nitrite/Nitrate Synthesis in Murine Macrophages by BCG Infections, Lymphokines, or Interferon- $\gamma$ ." *The Journal of Immunology*, 139(2):518-525, 1987, published in Baltimore, MD.

Bone, Roger C. "The Pathogenesis of Sepsis." *Ann. Int. Med.* 115:457-469, 1991. Published in USA.

Bone, Roger C. "A Critical Evaluation of New Agents for the Treatment of Sepsis." *JAMA* 266(12):1686-1691, 1991. Published in USA.

Glauser, M.P., et al. "Septic Shock: Pathogenesis." *The Lancet*, 338:732-736, 1991. Published in UK.

(List continued on next page.)

Primary Examiner—Chhaya D. Sayala  
 Attorney, Agent, or Firm—Arnold, White & Durkee

**[57] ABSTRACT**

The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock.

**9 Claims, 1 Drawing Sheet**